Physician profile
Lindsey Trutter
NPI 1518305002
$8,246.54
in general payments reported to CMS, 2019-2025
24 companies · $333 in 2025
The $333 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $295 · 2021: $340 · 2022: $1,100 · 2023: $4,148 · 2024: $1,587 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,804 · Travel and Lodging: $2,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.82 |
| Travel and Lodging | $2,264.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $2,159.60 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $2,025.71 | 2022-2025 | Impella |
| Boston Scientific Corporation | $1,019.81 | 2019-2025 | Watchman Flx, Eluvia, Resonate El Icd Vr |
| Abbott Laboratories | $707.76 | 2019-2025 | Ultreon, Xience Sierra, Diamondback Coronary |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $376.29 | 2020-2025 | Lifevest |
| Medtronic Vascular, INC. | $335.56 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $225.90 | 2022-2024 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $176.66 | 2022-2025 | Verquvo |
| Teleflex LLC | $155.75 | 2020-2023 | Guideliner |
| Janssen Pharmaceuticals, INC | $155.31 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $120.53 | 2021-2024 | |
| Pfizer INC. | $119.11 | 2021-2023 | |
| Amgen INC. | $100.06 | 2023-2025 | Repatha, Repatha |
| Biosense Webster, INC. | $96.51 | 2019-2020 | |
| Novo Nordisk INC | $80.40 | 2025 | Ozempic |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $68.88 | 2022-2023 | Indigo System |
| Acist Medical Systems, INC. | $66.20 | 2022-2023 | |
| Irhythm Technologies, INC. | $65.48 | 2022-2023 | Zio Xt Patch |
| Lantheus Medical Imaging, INC. | $52.50 | 2022-2023 | Definity |
| Lexicon Pharmaceuticals, INC. | $42.47 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.78 | 2022 | |
| Medtronic, INC. | $27.61 | 2024 | Micra |
| Amarin Pharma, INC. | $22.93 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $17.73 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Trutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.